Scalper1 News
Celgene’s (CELG) drug Abraxane outperformed its predecessor in a large study of early-stage breast cancer, making its potential market bigger than previously thought, according to one analyst. Celgene stock was up 2% in morning trading in the stock market today. From the San Antonio Breast Cancer Symposium on Thursday, Leerink analyst Howard Liang wrote that a German study of 1,200 patients taking neoadjuvant chemotherapy (i.e., drug therapy Scalper1 News
Scalper1 News